10-02-0	2 10:27am	From-Carella	Byrne,Bain,&Gilfillan			T-882 P.	001/010 F-99
	CARELLA, BYRNE, BAIN, GILFILLAN CECCHI, STEWART & OLSTEIN 6 Becker Farm Road Roseland, New Jersey 07068 (973) 994-1700 (973) 994-1744 (FAX) DATE: October 2, 2002			ŧ	OPERATOR: JaniceS TIME COMPLETED: EXT. NO.: 524		
				OUR FILE NO.: 176650-96			
	NAME	,	FIRM	м :		FAX	NO.
•	Diana Dudash		PTO			703-746-5058	
-							
-							
	FROM: William Squire Total Pages Including Transmittal Sheet: 10						
,	COMMEN	TS:	As requested, I am (filed June 3, 2002) 2002.	faxing our Ar in response	nendment mailed to the Office Acti	on May 2 ion dated F	4, 2002, Seb. 25,
·	IF YOU HA THE NUMI 994-1700 (E	BER OF PAG	ROBLEMS WITH GES NOTED, PLEA	THIS TRANS SE CONTAC	SMISSION, OR I	DO NOT I ERATOR	RECEIVE AT (973)
	contain info Olstein, whi facsimile is specifically a hereby notifi prohibited.	ich is confice intended only authorized to that any of you have r	NOTE: The document the law firm of Office the law for legally for the use of the preceive it. If the ordissemination, distreceived this telecopy the return of the original to the original to the original to the legal the return of the original to the legal to the l	Carella, Byrne y privileged. individual name receiving it ibution or co in error, pleas	The information and above and ot is not the intended by of this communities and the control of t	Cecchi, Son contained hers who led recipient tunication ephone im	Stewart & ed in this have been at, you are is strictly
	The original	l of this docu	ıment will be sent by	y:			
		Ordinary Mai Messenger	il		Overnight Mail This will be the	only form	

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT

Suggy S. Chrai

SERIAL NO.

09/774,346

FILED

January 31, 2001

FOR

Pharmaceutical Product and Method of Making

EXAMINER

Michael A. Williamson

ART UNIT:

1616

ATTORNEY DOCKET:

176650-96

AMENDMENT UNDER 37 CFR 1.111

Box Non-fee Amendment Commissioner for Patents Washington, DC 20231

Sir:

This paper is in response to the Office Action dated February 25, 2002 having a response due date set to expire on May 28, 2002.

IN THE CLAIMS

Cancel claims 36-37.

Amend the claims as follows:

1 (Twice amended). A product comprising:

a substrate; and

a plurality of discrete pharmaceutical or diagnostic unit dosage forms associated with the substrate, each unit dosage form including at least one active ingredient, said at least one active ingredient being deposited in separate discrete spaced locations on the substrate, each location comprising the active ingredient present in ach of the unit

